Which medication should be observed for 6 hours after administration due to bradycardia risk?

Gilenya is known to carry a risk of bradycardia, particularly following its first dose. When it is administered, patients are typically advised to be monitored for at least 6 hours to assess heart rate and blood pressure changes. This is due to the medication's mechanism of action, which involves the modulation of sphingosine-1-phosphate receptors and can cause a decrease in heart rate.

The monitoring is a critical part of ensuring patient safety, as significant bradycardia can lead to dizziness, fatigue, or more severe cardiovascular issues. Recognizing this risk is essential for healthcare providers when prescribing Gilenya, ensuring timely intervention if any adverse effects occur.

The other medications listed do not have the same requirement for extended monitoring post-administration due to bradycardia risks, which distinguishes Gilenya as the correct answer for this question.